Literature DB >> 7089870

Development of a transplantable model of pancreatic duct adenocarcinoma.

C M Townsend, R B Franklin, F B Gelder, E Glass, J C Thompson.   

Abstract

We report here the first development of a continuous cell line in tissue culture of an animal pancreatic duct adenocarcinoma that is histologically similar to human pancreatic duct adenocarcinoma. A primary pancreatic duct adenocarcinoma, induced in a male Syrian golden hamster after 23 weeks of weekly subcutaneous injection of N-nitrobis (2-hydroxypropyl)amine, was minced and injected subcutaneously into three hamsters. After 8 weeks, a single tumor was apparent. Subsequent passages of fragments into the cheek pouches were performed at 3- to 4-week intervals. After five passages, minced fragments of a tumor were placed in tissue culture. Colonies appeared by 7 days; an epitheloid cell line, without fibroblasts, was established by 60 days. Single-cell suspensions, injected into hamster cheek pouches or subcutaneously, produced tumors in a dose-dependent fashion. Spent culture medium of tissue culture cells and saline extracts of freshly excised tumors contained pancreatic oncofetal antigen-like activity.

Entities:  

Mesh:

Year:  1982        PMID: 7089870

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  12 in total

1.  Cyclosporine and alpha-difluoromethylornithine exhibit differential effects on colon and pancreatic cancer in vitro.

Authors:  R Saydjari; C M Townsend; S C Barranco; J C Thompson
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

2.  Blood-group antigen expression during pancreatic cancer induction in hamsters.

Authors:  P M Pour; E Uchida; D A Burnett; Z Steplewski
Journal:  Int J Pancreatol       Date:  1986-12

3.  Augmentation of chemically induced pancreatic and bronchial cancers by epidermal growth factor.

Authors:  R A Malt; J F Chester; H A Gaissert; J S Ross
Journal:  Gut       Date:  1987       Impact factor: 23.059

4.  Development of intrapancreatic transplantable model of pancreatic duct adenocarcinoma in Syrian golden hamsters.

Authors:  H Egami; T Tomioka; M Tempero; D Kay; P M Pour
Journal:  Am J Pathol       Date:  1991-03       Impact factor: 4.307

5.  K-ras and p53 mutations in hamster pancreatic ductal adenocarcinomas and cell lines.

Authors:  N Erill; M Cuatrecasas; F J Sancho; A Farré; P M Pour; F Lluís; G Capellá
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

6.  A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice.

Authors:  B J Drucker; F M Marincola; D Y Siao; T A Donlon; C D Bangs; W D Holder
Journal:  In Vitro Cell Dev Biol       Date:  1988-12

7.  Comparison of the cellular pharmacology of doxorubicin in resistant and sensitive models of pancreatic cancer.

Authors:  B K Chang; J A Gregory
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  Differential effect of submandibular gland resection on the growth of pancreatic cancer in cheek pouch and subcutaneous tissue.

Authors:  S Sumi; C M Townsend; T Uchida; J C Thompson
Journal:  Int J Pancreatol       Date:  1993-02

9.  Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters.

Authors:  Sergia Bortolanza; Maria Bunuales; Itziar Otano; Gloria Gonzalez-Aseguinolaza; Carlos Ortiz-de-Solorzano; Daniel Perez; Jesus Prieto; Ruben Hernandez-Alcoceba
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

10.  Differential sensitivity of pancreatic and colon cancer to cyclosporine and alpha-difluoromethylornithine in vivo.

Authors:  R Saydjari; C M Townsend; S C Barranco; J C Thompson
Journal:  Invest New Drugs       Date:  1988-12       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.